CN114395596A - 一种大豆咖啡灵芝生物活性肽的制备方法和应用 - Google Patents
一种大豆咖啡灵芝生物活性肽的制备方法和应用 Download PDFInfo
- Publication number
- CN114395596A CN114395596A CN202111551229.0A CN202111551229A CN114395596A CN 114395596 A CN114395596 A CN 114395596A CN 202111551229 A CN202111551229 A CN 202111551229A CN 114395596 A CN114395596 A CN 114395596A
- Authority
- CN
- China
- Prior art keywords
- coffee
- soybean
- ganoderma lucidum
- ganoderma
- bioactive peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000068988 Glycine max Species 0.000 title claims abstract description 53
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 53
- 240000007154 Coffea arabica Species 0.000 title claims abstract description 51
- 235000016213 coffee Nutrition 0.000 title claims abstract description 51
- 235000013353 coffee beverage Nutrition 0.000 title claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 30
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 30
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000222336 Ganoderma Species 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 229940088598 enzyme Drugs 0.000 claims abstract description 11
- 230000000415 inactivating effect Effects 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 6
- 108090000526 Papain Proteins 0.000 claims abstract description 5
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 5
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 5
- 239000004365 Protease Substances 0.000 claims abstract description 5
- 102000004142 Trypsin Human genes 0.000 claims abstract description 5
- 108090000631 Trypsin Proteins 0.000 claims abstract description 5
- 239000012670 alkaline solution Substances 0.000 claims abstract description 5
- 229940055729 papain Drugs 0.000 claims abstract description 5
- 235000019834 papain Nutrition 0.000 claims abstract description 5
- 229940111202 pepsin Drugs 0.000 claims abstract description 5
- 239000012588 trypsin Substances 0.000 claims abstract description 5
- 239000004382 Amylase Substances 0.000 claims abstract description 3
- 102000013142 Amylases Human genes 0.000 claims abstract description 3
- 108010065511 Amylases Proteins 0.000 claims abstract description 3
- 240000003183 Manihot esculenta Species 0.000 claims abstract description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims abstract description 3
- 235000019418 amylase Nutrition 0.000 claims abstract description 3
- 239000012460 protein solution Substances 0.000 claims abstract description 3
- 229960001322 trypsin Drugs 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002131 composite material Substances 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 238000005728 strengthening Methods 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 206010002660 Anoxia Diseases 0.000 abstract description 2
- 241000976983 Anoxia Species 0.000 abstract description 2
- 206010011224 Cough Diseases 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000007953 anoxia Effects 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000009545 invasion Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 230000003860 sleep quality Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 150000002333 glycines Chemical class 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 235000013373 food additive Nutrition 0.000 description 12
- 239000002778 food additive Substances 0.000 description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 9
- 229960002737 fructose Drugs 0.000 description 9
- 239000005715 Fructose Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940080701 chymosin Drugs 0.000 description 6
- 108010007119 flavourzyme Proteins 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 108090000145 Bacillolysin Proteins 0.000 description 4
- 235000005976 Citrus sinensis Nutrition 0.000 description 4
- 240000002319 Citrus sinensis Species 0.000 description 4
- 108091005507 Neutral proteases Proteins 0.000 description 4
- 102000035092 Neutral proteases Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 229930189775 mogroside Natural products 0.000 description 4
- 229940013618 stevioside Drugs 0.000 description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 3
- 108091005658 Basic proteases Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 244000148687 Glycosmis pentaphylla Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Anesthesiology (AREA)
Abstract
一种大豆咖啡灵芝生物活性肽的制备方法和应用，原料包括大豆、灵芝和咖啡，具体方法为：将大豆30‑50份，灵芝5‑15份，咖啡15‑40份比例混合。首先制备分离碱性蛋白溶液，将大豆、灵芝、咖啡分离，碱性溶液加入胃蛋白酶、胰蛋白酶、木瓜蛋白酶、木薯淀粉酶，酶解后，灭酶。本发明能够益气血，安心神，健脾胃，降糖，抗缺氧，清除自由基，镇咳，祛痰，平喘，降压降脂强心的效果；同时调理身体，维护人体机能平衡稳定，增强自身免疫力，抗过敏，抗氧化，延缓衰老；抵抗病菌入侵，减少疾病发生。对神经***有镇静，安定，镇痛的作用，改善睡眠质量；提高抗辐射能力的作用。对烟酒人群的五脏补益养护，保肝护肝。
Description
技术领域
本发明涉及大豆咖啡灵芝生物活性肽的制备领域，尤其涉及一种大豆咖啡灵芝生物活性肽的制备方法和应用。
背景技术
生物活性肽(Bioactive Peptides，BAP)是蛋白质中20种天然氨基酸以不同组成和排列方式构成的从二肽到复杂的线性、环形结构的不同肽类的总称，是源于蛋白质的多功能化合物。生物活性肽具有多种人体代谢和生理调节功能，易消化吸收，有促进免疫、激素调节、抗菌、抗病毒、降血压、降血脂等作用，是当前国际食品界最热门的研究课题和极具发展前景的功能因子。
现有的生物活性肽种类中并没有以大豆、灵芝和咖啡为原料的，导致生物活性肽的种类不够丰富，营养成分也不够多样，无法满足消费者的需求。
发明内容
针对现有技术中的上述不足，本发明提供了一种大豆咖啡灵芝生物活性肽的制备方法和应用。
为了达到上述发明目的，本发明采用的具体方案为：
一种大豆咖啡灵芝生物活性肽的制备方法，原料包括大豆、灵芝和咖啡，具体方法为：将大豆30-50份，灵芝5-15份，咖啡15-40份比例混合，首先制备分离碱性蛋白溶液，将大豆、灵芝、咖啡分离，碱性溶液加入胃蛋白酶、胰蛋白酶、木瓜蛋白酶、木薯淀粉酶，酶解后，灭酶。
进一步，所述大豆、灵芝和咖啡的蛋白原料经胃蛋白酶和胰蛋白酶酶解制成。
进一步，所述大豆、灵芝和咖啡蛋白原料经木瓜蛋白酶或复合酶Protamex酶解制成。
进一步，所述大豆灵芝咖啡肽的质量比为(1.3-3.1)：(1.3-2.2)：(1.8-4.1)。
进一步，所述大豆灵芝咖啡复合肽的质量比为(1.3-4.0)：0.42。
进一步，复合小分子离子肽液去除表面杂质，离心后所得上清液，即获得复合大豆灵芝咖啡小分子(离子)肽。
一种大豆咖啡灵芝生物活性肽的应用，按1％-5％的比列和纯净水调合，再加入调味剂、植物防腐剂、纯净水，得到原料，制成化妆品、食品或药品及保健品。
本发明的有益效果为：
本发明通过特定工艺制备获得了特定分子量区间的复合植物小分子大豆咖啡灵芝肽液。三者或四者在合适比例下组成合物，能够以较少的使用量，达到益气血，安心神，健脾胃，降糖，抗缺氧，清除自由基，镇咳，祛痰，平喘，降压降脂强心的效果。同时调理身体，维护人体机能平衡稳定，改善衰老所致的免疫功能的衰退，增强自身免疫力，抗过敏，抗氧化，延缓衰老。抵抗病菌入侵，减少疾病发生。对神经***有镇静，安定，镇痛的作用，改善睡眠质量。对亚健康人群有改善亚健康，摆脱亚健康状态，提高抗辐射能力的作用。对烟酒人群的五脏补益养护，保肝护肝。
具体实施方式
以下通过具体实施例进一步描述本发明，但本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内，对本发明进行的变更、组合或替换，对于本领域的技术人员来说是显而易见的，且包含在本发明的范围之内。
一种大豆咖啡灵芝生物活性肽的制备方法和应用，首先制备大豆和咖啡及灵芝按30-70份，5-15份，15-40份混合分离蛋白碱性溶液。将大豆、咖啡和灵芝分离碱性溶液加入Alcalase蛋白酶，酶解后，灭酶，离心，取得上清液，即为复合大豆咖啡灵芝肽液。在温室下对大豆灵芝咖啡肽液进行回流超滤操作，在超滤操作同时进行活性炭的吸附除臭。所述超滤操作采用9支超滤膜进行串联截留分子量为2500Da～4500Da，压力为0.2Mpa～1.2Mpa，处理5～20min，脱除相对分子质量≦2500Da的无机盐离子后，收集滤出大豆咖啡灵芝复合肽液。后在温室下加入橙子、草莓液等调味剂及低聚果糖、木糖醇、水果糖等改善成品复合肽液的口感。生产出具有保健和治疗为主的双重作用的口服液。
实施例1
原料组成(重量份)：复合大豆灵芝咖啡复合肽80份、结晶果糖和食品添加剂2份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
S1.将复合大豆灵芝咖啡肽溶于水中(物料与水的质量比为1:10)，用1mol/L NaOH溶液调节溶液pH为8.5，加入碱性蛋白酶酶解，然后用1mol/L HC1溶液调节pH为7，加入中性蛋白酶酶解，添加量为2500U/kg，结束后灭酶，离心，取上清液，用截留分子量为1000u的超滤膜超滤，得到分子量小于1000u的滤过液，得到大豆灵芝咖啡复合低聚肽浓缩液。
S2.将大豆灵芝咖啡低聚肽混合，溶解于水中(物料与水的质量比为1:10)，用1mol/L HC1溶液调节pH为7，加入a-糜凝乳酶和风味蛋白酶反应，所述a-糜凝乳酶的添加量为2000U/kg，所述风味蛋白酶的添加量为3000U/kg，结束后灭酶，离心，取上清液，透析，-10℃温度下预冷50min，得到复合肽浓缩液，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽口服液。
实施例2
原料组成(重量份)：大豆灵芝咖啡复合肽75份、结晶果糖15份和食品添加剂1.5份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
S1.将大豆灵芝咖啡肽溶于水中(物料与水的质量比为1:10)，用1mol/L NaOH溶液调节溶液pH为8.5，加入碱性蛋白酶酶解，然后用1mol/L HC1溶液调节pH为7，加入中性蛋白酶酶解，添加量为2500U/kg，结束后灭酶，离心，取上清液，用截留分子量为1000u的超滤膜超滤，得到分子量小于1000u的滤过液，得到大豆灵芝咖啡复合低聚液态。
S2.将大豆灵芝咖啡低聚肽混合，溶解于水中(物料与水的质量比为1:10)，用1mol/L HC1溶液调节pH为6，加入a-糜凝乳酶和风味蛋白酶反应，所述a-糜凝乳酶的添加量为2000U/kg，所述风味蛋白酶的添加量为3000U/kg，结束后灭酶，离心，取上清液，得到复合肽浓缩液，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽口服液。
对比例1
原料组成(重量份)：大豆灵芝咖啡复合肽75份、结晶果糖15份和食品添加剂1.5份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
将大豆灵芝咖啡复合肽，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽口服液。
对比例2
原料组成(重量份)：大豆灵芝咖啡复合肽75份、结晶果糖15份和食品添加剂1.5份。
所述食品添加剂由以下原料按重量份混合而成：甜橙香精0.5份，降苦味香精0.5份，罗汉果甜苷0.4份，甜菊糖苷0.05份。
一种植物肽的制备方法，包括以下步骤：
将大豆灵芝咖啡肽混合，溶解于水中(物料与水的质量比为1:10)，用1mol/L HC1溶液调节pH为6，加入a-糜凝乳酶和风味蛋白酶反应，所述a-糜凝乳酶的添加量为2000U/kg，所述风味蛋白酶的添加量为3000U/kg，结束后灭酶，离心，取上清液，加入结晶果糖和食品添加剂，溶解混合均匀，制得植物肽液口服液。
以上所述仅为本发明专利的较佳实施例而已，并不用以限制本发明专利，凡在本发明专利的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明专利的保护范围之内。
Claims (7)
1.一种大豆咖啡灵芝生物活性肽的制备方法，其特征在于，原料包括大豆、灵芝和咖啡，具体方法为：将大豆30-50份，灵芝5-15份，咖啡15-40份比例混合，首先制备分离碱性蛋白溶液，将大豆、灵芝、咖啡分离，碱性溶液加入胃蛋白酶、胰蛋白酶、木瓜蛋白酶、木薯淀粉酶，酶解后，灭酶。
2.根据权利要求1所述的一种大豆咖啡灵芝生物活性肽的制备方法，其特征在于：所述大豆、灵芝和咖啡的蛋白原料经胃蛋白酶和胰蛋白酶酶解制成。
3.根据权利要求1所述的一种大豆咖啡灵芝生物活性肽的制备方法，其特征在于：所述大豆、灵芝和咖啡蛋白原料经木瓜蛋白酶或复合酶Protamex酶解制成。
4.根据权利要求1-3任意一项所述的一种大豆咖啡灵芝生物活性肽的制备方法，其特征在于：所述大豆灵芝咖啡肽的质量比为(1.3-3.1)：(1.3-2.2)：(1.8-4.1)。
5.根据权利要求1-3任意一项所述的一种大豆咖啡灵芝生物活性肽的制备方法，其特征在于：所述大豆灵芝咖啡复合肽的质量比为(1.3-4.0)：0.42。
6.根据权利要求1所述的一种大豆咖啡灵芝生物活性肽的制备方法，其特征在于：复合小分子离子肽液去除表面杂质，离心后所得上清液，即获得复合大豆灵芝咖啡小分子(离子)肽。
7.一种大豆咖啡灵芝生物活性肽的应用，其特征在于：按1％-5％的比列和纯净水调合，再加入调味剂、植物防腐剂、纯净水，得到原料，制成化妆品、食品或药品及保健品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551229.0A CN114395596A (zh) | 2021-12-17 | 2021-12-17 | 一种大豆咖啡灵芝生物活性肽的制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551229.0A CN114395596A (zh) | 2021-12-17 | 2021-12-17 | 一种大豆咖啡灵芝生物活性肽的制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114395596A true CN114395596A (zh) | 2022-04-26 |
Family
ID=81226905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111551229.0A Pending CN114395596A (zh) | 2021-12-17 | 2021-12-17 | 一种大豆咖啡灵芝生物活性肽的制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114395596A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489923A (zh) * | 2003-09-16 | 2004-04-21 | 北京陶正生物工程技术有限公司 | 大豆蛋白活性肽的制作方法 |
| CN104431208A (zh) * | 2014-12-29 | 2015-03-25 | 陕西天宝大豆食品技术研究所 | 肽咖啡及其制备方法 |
| CN110037163A (zh) * | 2019-04-24 | 2019-07-23 | 王书敏 | 一种复合植物蛋白肽的制备方法 |
| CN111358009A (zh) * | 2020-03-16 | 2020-07-03 | 赵秋萍 | 一种植物肽及其制备方法和应用 |
| CN111662946A (zh) * | 2020-07-17 | 2020-09-15 | 上海应用技术大学 | 一种灵芝水溶性蛋白酶解制备低聚肽的方法 |
-
2021
- 2021-12-17 CN CN202111551229.0A patent/CN114395596A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489923A (zh) * | 2003-09-16 | 2004-04-21 | 北京陶正生物工程技术有限公司 | 大豆蛋白活性肽的制作方法 |
| CN104431208A (zh) * | 2014-12-29 | 2015-03-25 | 陕西天宝大豆食品技术研究所 | 肽咖啡及其制备方法 |
| CN110037163A (zh) * | 2019-04-24 | 2019-07-23 | 王书敏 | 一种复合植物蛋白肽的制备方法 |
| CN111358009A (zh) * | 2020-03-16 | 2020-07-03 | 赵秋萍 | 一种植物肽及其制备方法和应用 |
| CN111662946A (zh) * | 2020-07-17 | 2020-09-15 | 上海应用技术大学 | 一种灵芝水溶性蛋白酶解制备低聚肽的方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103689733B (zh) | 一种大豆肽风味饮料的制备方法 | |
| US20220024974A1 (en) | Methods for producing a rice protein peptide and applications thereof | |
| CN105614899B (zh) | 一种低分子大豆肽及其制备方法 | |
| CN103689732B (zh) | 一种大豆肽风味饮料 | |
| CN111642666A (zh) | 一种人参提取物大豆肽粉固体饮料的制备方法 | |
| CN110205353A (zh) | 一种咸味增强肽及其制备方法和用途 | |
| CN101238904B (zh) | 一种鹰嘴豆豆芽汁茶及制备方法和用途 | |
| CN108220374A (zh) | 大豆活性肽的制备方法 | |
| CN111296849A (zh) | 抗衰老燕窝雪蛤鹿血胶原蛋白复合肽饮品及其制备方法 | |
| CN108546281A (zh) | 一种人参低聚肽及其制备方法和应用 | |
| CN111772194A (zh) | 补气安神、益精固肾的食品配方 | |
| CN107927653A (zh) | 一种提高免疫力的海参肽产品及其制备方法 | |
| CN1377590A (zh) | 大豆蛋白水解物的生产方法及应用 | |
| CN110499351A (zh) | 一种具有高ace抑制活性的大豆肽及其制备方法与应用 | |
| CN114395596A (zh) | 一种大豆咖啡灵芝生物活性肽的制备方法和应用 | |
| CN111329988A (zh) | 一种富含游离精氨酸的阿胶肽含片及其制备方法 | |
| CN101130801A (zh) | 一种降血压活性肽产品的制备 | |
| CN110810852A (zh) | 一种调节心血管功能的蚯蚓冻干粉的制备方法 | |
| CN104757655A (zh) | 一种地龙氨基酸饮料及其制作方法 | |
| CN114480539A (zh) | 一种大豆咖啡人参生物活性肽的制备方法和应用 | |
| CN114517219A (zh) | 一种大豆咖啡天麻生物活性肽的制备方法和应用 | |
| CN114480540A (zh) | 一种大豆咖啡山楂生物活性肽的制备方法和应用 | |
| CN114214380A (zh) | 一种大豆咖啡西洋参生物活性肽的制备方法和应用 | |
| CN114480536A (zh) | 一种大豆咖啡黄精生物活性肽的制备方法和应用 | |
| CN105586239A (zh) | 金银花果醋及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220426 |
|
| RJ01 | Rejection of invention patent application after publication |